Table 3.

Adverse events from the phase II study of lenvatinib plus everolimus for renal cell carcinoma

Adverse event	Lenvatinib/temsirolimus arm		Lenvatinib arm		Temsirolimus arm
	All grades, %	Grade ≥3, %	All grades, %	Grade ≥3, %	All grades, %	Grade ≥3, %
Diarrhea	85	20	72	12	34	2
Decreased appetite	51	6	58	4	18	0
Fatigue/asthenia	59	14	50	8	36	2
Vomiting	45	8	39	4	10	0
Nausea	41	6	52	8	16	0
Cough	37	0	17	2	30	0
Hypercholesterolemia	33	2	12	2	16	0
Decreased weight	31	2	48	6	8	0
Stomatitis	29	0	25	2	42	2
Hypertriglyceridemia	35	8	14	4	24	8
Hypertension	41	14	48	17	10	2
Peripheral edema	27	0	15	0	18	0
Abdominal pain	30	4	31	4	10	0
Hypothyroidism	24	0	37	2	2	0
Arthralgia	24	0	25	0	4	0
Dyspnea	24	2	21	2	22	8
Dysphonia	20	0	37	0	4	0
Pyrexia	22	2	10	0	10	2
Epistaxis	18	0	8	0	22	0
Proteinuria	22	4	31	19	14	2
Rash	18	0	17	0	22	0
Hyperglycemia	16	0	6	0	22	10
Back pain	20	4	21	0	14	0
Headache	18	2	25	4	10	2
Insomnia	18	2	14	0	2	0
Any TEAE	99	71	94	79	96	50

Abbreviation: TEAE, treatment‐emergent adverse event.